Journal

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

Read time: 1 mins

Published:24th Jan 2024

Author: Abou Dalle I, Dulery R, Moukalled N, Ricard L, Stocker N, El-Cheikh J et al.

Source: Blood Cancer Journal

Availability: Free full text

Ref.:Blood Cancer J. 2024 Jan 25;14(1):23.

DOI:10.1038/s41408-024-00989-w

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.

Read abstract on library site Access full article